IQV Stock Overview
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQVIA Holdings Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$186.20|
|52 Week High||US$285.61|
|52 Week Low||US$180.16|
|1 Month Change||-10.16%|
|3 Month Change||-13.52%|
|1 Year Change||-21.95%|
|3 Year Change||25.22%|
|5 Year Change||94.38%|
|Change since IPO||342.18%|
Recent News & Updates
Is Now The Time To Look At Buying IQVIA Holdings Inc. (NYSE:IQV)?
IQVIA Holdings Inc. ( NYSE:IQV ) received a lot of attention from a substantial price movement on the NYSE over the...
IQVIA: Rebound Is Likely But Downtrend Is Still Intact (Technical Analysis)
Summary IQVIA Holdings Inc. bottomed on June 16 and has since rallied 28% in a breakout attempt that finally failed. IQVIA Holdings stock is a strong leader in its industry, and despite some recent weakness, has significantly outperformed the broader healthcare sector. With 115% performance over the past 5 years, IQVIA outperformed its industry reference by almost 10 times. IQVIA Holdings stock has likely a relatively low downside risk when considering its closest support levels, and a price target seen 24% higher. Investment thesis IQVIA Holdings Inc. (IQV) has been in a moderate downtrend since the beginning of 2022. While recently only showing some sporadic relative strength, the stock could perform significantly better than its industry in the past 5 years. The stock has tried to form a new uptrend, but failed and has since retraced to important support levels. Although companies providing health information services began to perform better in the past 3 months, the industry is still the worst performer in the healthcare sector in the past year. IQV stock is experiencing a short-term selloff and has to demonstrate if this will lead to lower lows or if the closest support will allow the stock to rebound. If the support holds, my most likely price target is set at $254, but the recent setup could suggest more downside risk, which I see possibly leading to around $194-$192, resulting in a short-term risk/reward ratio of 3.75 from its latest closing price. A quick look at the big picture The healthcare sector in the U.S. is among the winners in the last 3 months, led by a rebound in biotechnology stocks, followed by companies providing healthcare plans and part of the medical care facilities industry. Companies in the health information industry performed worse in the group, though their negative trend of the past 12 months seemed to improve recently. Finviz Finviz The NASDAQ Health Care Index (IXHC) began to improve in July and showed significant relative strength in August when compared to the broader healthcare sector. Despite a recent rebound, the industry reference seems to struggle to overcome its long-term downtrend as it got rejected on its EMA200 and is now priced under its EMA50, with all its most important moving averages still negatively oriented. Author, using TradingView Looking back even further, IQVIA significantly outperformed its main sector reference and could establish itself remarkably better in its industry, reporting 115.83% performance over the past 5 years, almost 10 times better than its industry reference, and more than doubling the performance of the Health Care Select Sector SPDR (XLV). Author, using SeekingAlpha.com Where are we now? Since my last article, "IQVIA A Smart Choice In A High-Inflation Environment," published on April 29, 2022, where I suggested the stock may be in an unfavorable technical situation, the stock has effectively bottomed only on June 16. It instantly formed a strong rebound that led the stock 28% higher until mid-August. The recent retracement is characterized by increasing sell volume that leads the stock to break all its relevant supports, and even form a gap down in its last trading session. The EMA200, which suggested a flattening of its downtrend, has instead since turned negative again, while the stock seems quite extended under its most important moving averages. Author, using TradingView Although it's still early to determine if a significant new downtrend is forming or if this pullback is all part of the bottoming process, it's important to note that the last session, despite starting with a gap down and massively higher volume, has finally prevented the stock from falling further. This is a common behavior broadly observed when buyers are showing more interest at certain price levels. What is coming next? I expect IQVIA stock to continue to moderately outperform its reference sector, while slowly improving its performance in its industry in the near term, as the stock still looks fundamentally undervalued. Technically, the stock seems to be more likely to continue its short-term downside movement, trying to form a sound base, from which it would start its next attempt to break out if more buy-side volume shows up and the stock can overcome its overhead resistance. Author, using TradingView My projections suggest the most likely short-term price target to be set at $254, while I qualify the downside risk at around $194-$192, with possible catalysts coming up next, as the company will report its Q3 results towards the end of October.
With EPS Growth And More, IQVIA Holdings (NYSE:IQV) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
GSK, Iqvia launch Vaccine Track platform to highlight vaccine trends publicly in US
GSK (NYSE:GSK) Iqvia (NYSE:IQV) launched Vaccine Track, a platform to track vaccination data across the U.S. The companies said the platform will be for use by public health officials, industry leaders and medical professionals to strengthen vaccination data transparency, raise awareness and publicly share vaccination trends to help improve routine adult vaccinations. Vaccine Track will help users identify vaccination trends for adults above 19 years of age in the U.S. across multiple vaccines; scan immunization claims data nationally and sub-nationally across years; track trends based on 2019 pre-COVID-19 baseline vaccination uptake; and bring to light differences that exist based on demographics, such as age, gender, race and ethnicity, among others. The companies said the platform currently spans information from January 2019 to December 2021 and will be updated on a quarterly basis. "For the first time, Vaccine Track brings quarterly data tracking and trends together in a comprehensive platform for immunization partners, decision makers and stakeholders," said Judy Stewart, GSK senior vice president and head of U.S. Vaccines.
|IQV||US Life Sciences||US Market|
Return vs Industry: IQV exceeded the US Life Sciences industry which returned -32% over the past year.
Return vs Market: IQV exceeded the US Market which returned -23.2% over the past year.
|IQV Average Weekly Movement||4.6%|
|Life Sciences Industry Average Movement||9.7%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: IQV is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: IQV's weekly volatility (5%) has been stable over the past year.
About the Company
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
IQVIA Holdings Inc. Fundamentals Summary
|IQV fundamental statistics|
Is IQV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IQV income statement (TTM)|
|Cost of Revenue||US$9.27b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||6.22|
|Net Profit Margin||8.21%|
How did IQV perform over the long term?See historical performance and comparison